论文部分内容阅读
目的:观察痰湿瘀阻方对多囊卵巢综合征(PCOS)大鼠卵巢组织抑制素β(INH-β)、纤溶酶原激活物抑制剂-1(PAI-1)表达的影响,探讨痰湿瘀阻方治疗PCOS的机制。方法:选取SPF级健康雌性大鼠40只,随机抽取10只为空白组,余30只采用来曲唑诱导建造大鼠PCOS模型,造模成功后,随机分为模型组、二甲双胍组、痰湿瘀阻方组,每组10只。各组给予相应处理,测量实验前后卵巢重量,ELISA法检测卵巢组织INH-β、PAI-1的表达。结果:模型组INH-β、PAI-1的表达较其他各组高(P<0.05),痰湿瘀阻方组明显低于模型组(P<0.05),且低于二甲双胍组(P<0.05),痰湿瘀阻方组与空白组比较,差异无统计学意义(P>0.05);痰湿瘀阻方组体重指数低于其他各组(P<0.05)。结论:痰湿瘀阻方能够治疗PCOS,可能与其降低卵巢组织INH-β、PAI-1有关。
Objective: To observe the effect of phlegm and dampness obstructing prescription on the expression of ovarian endostatin β (INH-β) and plasminogen activator inhibitor-1 (PAI-1) in the rats with polycystic ovary syndrome (PCOS) The Mechanism of Phlegm-dampness and Stagnation for Treating PCOS. Methods: Forty SPF healthy female rats were randomly selected. Ten rabbits were randomly selected as blank group. Thirty rabbits were induced with letrozole to induce PCOS model. After the model was established successfully, they were randomly divided into model group, metformin group, Stasis group, each group of 10. The rats in each group were given the corresponding treatment, the ovarian weight was measured before and after the experiment, and the expression of INH-β and PAI-1 in ovarian tissue was detected by ELISA. Results: The expressions of INH-β and PAI-1 in model group were significantly higher than those in other groups (P <0.05), and those in phlegm-dampness and stasis group were significantly lower than those in model group (P <0.05) ), There was no significant difference between the two groups (P> 0.05). The body mass index of phlegm-dampness-resistance group was lower than other groups (P <0.05). Conclusion: Phlegm-dampness-blocking prescription can treat PCOS, which may be related to the decrease of INH-β and PAI-1 in ovarian tissue.